Cytosolic phospholipase A 2 α (cPLA 2 α) is an important enzyme of the inflammation cascade. Therefore, inhibitors of cPLA 2 α are assumed to be promising drug candidates for the treatment of inflammatory disorders. Recently we have found that indole-5-carboxylic acid with a 3-(4-octylphenoxy)-2-(phenoxycarbonylamino)propyl substituent in position 1 is an inhibitor of cPLA 2 α. We have now synthesized a corresponding derivative with the indole heterocycle replaced by an indazole (4) employing an analogous reaction sequence as for the synthesis of the indole derivative. Besides, a more convergent synthesis for 4 was established using an aziridine as central intermediate. Furthermore, a chiral-pool based enantioselective synthesis was developed for the synthesis of (R)-and (S)-4. Starting compound for both enantiomers was the (R)-serine derived oxazolidine (R)-25. Compound 4 proved to be a moderate inhibitor of cPLA 2 α, with the S-enantiomer being twice as active as the R-enantiomer. The racemate 4 and the enantiomers (R)-and (S)-4 showed a high in vitro metabolic stability in rat liver S9 fractions.
Introduction
Cytosolic phospholipase A 2 α (cPLA 2 α) is an esterase that selectively cleaves the sn-2 position of arachidonoyl-glycerophospholipids of biomembranes to generate free arachidonic acid and lysophospholipids. 1, 2 Subsequent metabolism of these products leads to a variety of inflammatory mediators including prostaglandins, leukotrienes and platelet activating factor (PAF). Mice with cPLA 2 α deficiency display a reduced eicosanoid production and are resistant to disease in a variety of models of inflammation. 3 Therefore, cPLA 2 α is considered as a target for the treatment of inflammatory diseases, such as rheumatoid arthritis, atopic dermatitis and Alzheimer's disease. [4] [5] [6] Today several potent inhibitors of cPLA 2 α are known, 7, 8 which show activity in diverse animal models of inflammation after systemic or local application. However, none of these agents is actually in clinical development.
We have found that certain 1-(indol-1-yl)propan-2-ones, such as compound 1 (Fig. 1) , inhibit cPLA 2 α with high potency. 9 The latter compound shows structural similarities to the propan-2-one inhibitor ARC-70484XX developed by AstraZeneca. 10 An important part of the pharmacophore of these substances is the activated electrophilic ketone moiety present in the middle part of the molecules. This structural element is supposed to form reversible covalent binding interactions with a serine residue of the active site of cPLA 2 α. Recent studies have shown that 1-(indol-1-yl)propan-2-ones are extensively metabolized in vitro as well as in vivo. 11, 12 Especially, the activated ketone is reduced to an alcohol resulting in compounds, which do not inhibit cPLA 2 α any more. Therefore, we have replaced the ketone by metabolically more stable polar moieties such as acyloxy, acylamino, urea and carbamate. 13 These variations led to a more or less pronounced drop of inhibitory potency. One of the most active compounds of the investigated substances was the carbamate substituted indole-5-carboxylic acid 2, which possessed an IC 50 against cPLA 2 α in the micromolar range. Because structure-activity relationship studies on the 1-(indol-1-yl)propan-2-ones have revealed that replacement of the indole scaffold of 1 by an indazole (3) led to an about fivefold increase of activity, 14 we wanted to synthesize and evaluate the corresponding carbamate-substituted indazole derivative 4. In contrast to the ketones 1 and 3, the carbamates 2 and 4 possess a stereogenic centre resulting in R-and S-configurated products. A further aim of this study, therefore, was to develop enantioselective syntheses for the enantiomers of 4 and to determine the influence of the configuration of this compound on cPLA 2 α inhibition.
Results and discussion

Chemistry
For the preparation of the indazole 4 the synthetic route developed for the synthesis of the corresponding indole 2 13 was used (Scheme 1). Starting material was indazole-5-carboxylic acid (5) , which first was converted into its tert-butylester 8 employing a reaction sequence published for the synthesis of tert-butyl benzotriazole-5-carboxylate. 15 Treatment of 8 with epichlorohydrin in presence of KOH and tetrabutylammonium bromide led to 9, which was reacted with 4-octylphenol to obtain the secondary alcohol 10. The alcohol functionality of this compound was converted to a mesylate (11) by reaction with methanesulfonyl chloride. From the latter intermediate the azide 12 was obtained by treatment with trimethylsilyl azide and tetrabutylammonium fluoride. Catalytic hydrogenation of the azide group of 12 with Pd on charcoal led to the amine-substituted compound 13. Reaction of this with phenyl chloroformate in presence of an amine base followed by hydrolysis of the tert-butyl ester with trifluoroacetic acid gave the desired target compound 4. In Scheme 2, an alternative approach for the synthesis of 4 is outlined, which is more convergent in respect of the variation of the octylphenoxy-part of 4 during the course of structure-activity studies. This synthetic route started from indazole-5-carboxylic acid, which was converted into its allyl ester (15) by reaction with allyl bromide in presence of K 2 CO 3 . Using Cs 2 CO 3 as base, the indazole ester 15 was alkylated with epichlorohydrin in position 1 yielding the oxiranylmethylindazole derivative 16. The oxiranyl ring of 16 was opened to a azidoalcohol by reaction with sodium azide. 16 Then the azido group of 17 was transformed to an amine (18) by treatment with triphenylphosphine, which in turn was protected with BOC using di-tert-butyl dicarbonate. with varying substituents at the phenoxy-residue can be obtained from a common intermediate (here 21) in only four steps instead of six necessary in the synthesis described above (Scheme 1). Due to the chiral centre present in 4, this compound exists as two enantiomers. For the determination of their eudismic ratio, additionally an enantioselective, chiral-pool based synthetic approach was established. The synthesis of the R-configurated enantiomer of 4 started from the commercially availably, (R)-serine derived oxazolidine (R)-25, 18 which was converted to the tosylate (R)-27 as previously described (Scheme 3). 19, 20 This central intermediate was reacted with 4-octylphenol to yield the phenol ether (S)-29. The acetone protecting group was removed by reaction with p-toluenesulfonic acid and the alcohol moiety of (R)-30 was converted to a tosyl ester with p-toluenesulfonyl chloride. Treatment of obtained compound (R)-31 with allyl indazole-5-carboxylate in DMF in presence of NaH afforded the BOC protected 1-(2-aminopropyl)indazole derivative (R)-22. After deprotection of the BOC group, the amine moiety of resulting compound (R)-23 was reacted with phenyl chloroformate in presence of an amine base. Subsequent cleavage of the allyl ester group of resulting compound (R)-24 using Pd(0) catalysis led to the desired target compound (R)-4. The synthesis of the S-enantiomer of 4 is outlined in Scheme 4. With (R)-27, the identical central chiral intermediate was used as for the synthesis of the R-enantiomer. To get the antipodal configuration in the target compound, here the indazole heterocycle and not the 4-octylphenoxy residue was introduced at first into the molecule. After removing the acetone protection group of obtained compound (S)-32, the free alcohol moiety was esterified with tosyl chloride and the tosylate group substituted by a 4-octylphenoxy residue to afford (S)-22. From this compound (S)-4 was synthesized employing the same procedure as for the synthesis of (R)-4 from (R)-22. Chiral HPLC on a Chiralpak® IA column revealed that (R)-4 and (S)-4 were formed with 93% ee and 100% ee, respectively (for chromatograms see ESI †).
Biological evaluation
The target compounds were evaluated for cPLA 2 α inhibition in an assay using cPLA 2 α isolated from porcine platelets. 21 When measuring the inhibitory potency of 4, (S)-4 and (R)-4 it became evident that the data were strongly influenced by small impurities of the extreme potent indazolylpropan-2-one 3 (IC 50 : 0.0045 µM) present in the substances. The highest amounts of 3 (about 1% measured by HPLC/UV and MS) were found in 4 synthesized via the route shown in Scheme 1. The spectral data of the intermediates of the synthesis revealed that the ketone group was introduced into the molecule during the reduction of the azide 12 to the amine 13, and that the ketone impurity could not be separated in the following steps. The compounds synthesized by the sequences outlined in Schemes 2-4 contained smaller amounts of 3 (less than 0.1%). However, their inhibition values were also impaired by this substance. Therefore, all target compounds were purified by reversed phase HPLC. By this way, impurity 3 could be totally removed. The previously published lead compound 2 was newly synthesized from racemic 25 and allyl indole-5-carboxylate following the route outlined in Scheme 4 for the synthesis of (S)-4 (see ESI †). After cleaning up by reversed phase HPLC, for 2 an IC 50 value against cPLA 2 α of 26 µM was evaluated. In contrast to the ketones 1 and 3, the replacement of the indole heterocycle by an indazole did not increase inhibitory potency in case of the carbamates. With an IC 50 of 29 µM 4 was as active (15), NaH (dispersion in mineral oil), DMF, 80°C, 3 h; (g) trifluoroacetic acid, CH 2 Cl 2 , room temp., 2 h; (h) phenyl chloroformate, triethylamine, THF, room temp.; (i) tetrakis(triphenylphosphine)palladium(0), acetic acid, THF, room temp., 6 h.
Scheme 4 Reagents and conditions: (a) NaH, DMF, 80°C, 3 h; (b) 1. 1 M HCl, THF, 70°C, 3 h; 2. di-tert-butyl dicarbonate, triethylamine, methanol, room temp., 12 h; (c) p-toluenesulfonyl chloride, 4-dimethylaminopyridine, triethylamine, CH 2 Cl 2 , room temp., 12 h; (d) 4-octylphenol, NaH, DMF, 80°C, 3 h; (e) trifluoroacetic acid, CH 2 Cl 2 , room temp., 2 h; (f ) phenyl chloroformate, triethylamine, THF, room temp., 2 h; (g) tetrakis(triphenylphosphine)palladium(0), acetic acid, THF, room temp., 6 h.
as 2 ( Table 1 ). The two enantiomers of 4 showed a slight but significant difference in their IC 50 values: the S-enantiomer was about two-fold more active than the R-enantiomer.
As mentioned above, a drawback of the indazolylpropan-2-one 3 is its metabolic liability. In in vitro experiments it could be shown that the carbamate 4 is much more stable against metabolism by rat liver homogenate than 3. After incubation of 3 in presence of the co-factor NADPH only 8% of the parent compound could be recovered, under the same conditions still 80-90% of 4, (S)-4 and (R)-4 were present in the incubation mixture.
Conclusions
Taken together, we have developed new effective synthetic approaches for the synthesis of 4 as well as for its enantiomers (S)-4 and (R)-4. The biological evaluation of these compounds revealed that the increase of metabolic stability achieved by replacement of the ketone function of 3 by a carbamate moiety is accompanied by a drastic loss of cPLA 2 α inhibitory potency. The aim of further studies will be to improve cPLA 2 α inhibitory potency of 4 by structural variations.
Experimental section
Chemistry General. Column chromatography was performed on silica gel 60, particle size 0.040-0.063 mm, from Macherey & Nagel. Melting points were determined on a Büchi B-540 apparatus and are uncorrected. 1 H NMR spectra were recorded on a
Varian Mercury Plus 400 spectrometer (400 MHz), a Varian Unity Plus 600 spectrometer (600 MHz) or an Agilent VNMRS-600 spectrometer (600 MHz). 13 C NMR spectra were measured on a Varian Mercury Plus 400 spectrometer (101 MHz) or an Agilent VNMRS-600 spectrometer (151 MHz (16) . To a solution of 15 (0.070 g, 0.35 mmol) in DMF (5 mL) was added cesium carbonate (0.337 g, 1.03 mmol) followed by epichlorohydrin (0.190 mL, 1.74 mmol). The mixture was stirred at room temperature for 14 h. After addition of water (10 mL), the reaction mixture was exhaustively extracted with ethyl acetate. The combined organic phases were dried with Na 2 SO 4 , concentrated and chromatographed on silica gel (hexane-ethyl acetate, 9 : 1) to yield 16 as an oil (0.063 g, 70% 12 63 ± 6.7% (n = 9). Calculated log P values for 3 and 4 using Advanced Chemistry Development (ACD/Labs) Software V11.02: 6.5 and 8.4, respectively.
17 (19) . A solution of 18 (0.220 g, 0.71 mmol) in diethyl ether (10 mL) and methanol (6 mL) was treated at 0°C with triethylamine (0.11 mL, 0.79 mmol). Then di-tert-butyl dicarbonate (0.174 g, 0.80 mmol) was added and the mixture was stirred at room temperature for 2 h, concentrated and chromatographed on silica gel (hexane-ethyl acetate, 9 : 1 to 6 : 4) to afford 19 as an oil (0.256 g, 97% (21) . To a solution of 20 (2.25 g, 4.25 mmol) in CH 2 Cl 2 (40 mL) were added tetrabutylammonium hydrogen sulfate (0.231 g, 0.68 mmol) and freshly powdered potassium hydroxide (88%) (1.08 g, 17 mmol). The mixture was stirred at room temperature for 6 h. After addition of diethyl ether (100 mL), the mixture was filtered and the filtrate was concentrated to dryness. The residue was chromatographed on silica gel (hexane-ethyl acetate, 9 : 1) to yield 21 as an oil (1.26 g, 83% (22) . A solution of 21 (0.050 g, 0.14 mmol) in CH 2 Cl 2 (10 mL) was treated with 4-octylphenol (0.044 g, 0.21 mmol). After addition of 2 drops of BF 3 -etherate, the mixture was stirred at room temperature for 1 min, concentrated and chromatographed on silica gel (hexane-ethyl acetate, 9 : 1 to 8 : 2) to yield 22 as an oil (0.016 g, 20% 095 mmol) in dry THF (4 mL) were added dropwise at 0°C triethylamine (0.016 mL, 0.11 mmol) followed by phenyl chloroformate (0.015 mL, 0.12 mmol). The mixture was stirred at room temperature for 2 h, concentrated and chromatographed on silica gel (hexane-ethyl acetate, 9 : 1 to 8 : 2) to yield 24 as an oil (0.041 g, 74%). (4) . To a solution of 24 (0.038 g, 0.065 mmol) in dry THF (3 mL) was added under nitrogen tetrakis(triphenylphosphine)palladium(0) (0.008 g, 0.007 mmol). Then nitrogen was bubbled through the solution for 10 min. After addition of acetic acid (0.1 mL), the mixture was stirred at room temperature for 6 h, concentrated and chromatographed on silica gel (hexane-ethyl acetate-acetic acid, To a solution of 4-octylphenol (0.400 g, 1.94 mmol) in dry DMF (7 mL) was added sodium hydride (60% dispersion in mineral oil) (0.085 g, 2.13 mmol). The mixture was stirred at room temperature for about 30 min until no further development of hydrogen could be observed. A solution of (R)-tert-butyl 2,2-dimethyl-4-[(tosyloxy)methyl]oxazolidine-3-carboxylate ((R)-27) 19, 20 (0.897 g, 2.33 mmol) in DMF (7 mL) was added dropwise and the mixture was heated at 70°C for about 3 h. After addition of water (50 mL), the reaction mixture was exhaustively extracted with ethyl acetate. The combined organic phases were dried with Na 2 SO 4 , concentrated and chromatographed on silica gel (hexane-ethyl acetate, 19 : 1) to yield (S)-29 as an oil (0.661 g, 81% R)-30) . To a solution of (S)-29 (0.550 g, 1.31 mmol) in methanol (10 mL) was added p-toluenesulfonic acid monohydrate (0.113 g, 0.59 mmol). The mixture was stirred at room temperature for about 4 h. After neutralization with saturated sodium bicarbonate solution (10 mL), methanol was removed under reduced pressure and the aqueous residue was extracted with ethyl acetate (3 × 10 mL). The combined organic phases were dried with Na 2 SO 4 -22) . To a solution of allyl indazole-5-carboxylate (15) (0.114 g, 0.56 mmol) in dry DMF (5 mL) was added sodium hydride (60% dispersion in mineral oil) (0.024 g, 0.60 mmol). The mixture was stirred at room temperature for about 30 min until no further development of hydrogen could be observed. Then a solution of (S)-31 (0.200 g, 0.37 mmol) in DMF (5 mL) was added dropwise and the mixture was heated at 80°C for about 3 h. After addition of water (10 mL), the reaction mixture was exhaustively extracted with ethyl acetate. The combined organic phases were dried with Na 2 SO 4 , concentrated and chromatographed on silica gel (hexane-ethyl acetate, 9 : 1) to yield (R)-22 as an oil (0.121 g, 57%). S)-33) . A solution of (S)-32 (0.900 g, 2.17 mmol) in THF (10 mL) and 1 M HCl (10 mL) was heated at 70°C for 3 h. After evaporation of the solvent in vacuo, the residue was dissolved in methanol (20 mL) and triethylamine (1.04 mL, 7.46 mmol) and di-tert-butyl dicarbonate (0.543 g, 2.49 mmol) were added at 0°C. The mixture was stirred for 12 h, concentrated and chromatographed on silica gel 
